Wells Fargo
FTH

Wells Fargo’s Faeth Therapeutics FTH Stock Holding History

Wells Fargo’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$140 – 7419
2024
Q1 		$140 Hold
7
– – ﹤0.01% 6585
2023
Q4 		$91 Hold
7
– – ﹤0.01% 6796
2023
Q3 		$106 Hold
7
– – ﹤0.01% 6758
2023
Q2 		$150 Buy
7
+1
+17% +$29 ﹤0.01% 6777
2023
Q1 		$188 Hold
6
– – ﹤0.01% 6792
2022
Q4 		$183 Hold
6
– – ﹤0.01% 6639
2022
Q3 		$0 Buy
6
+3
+100% +$118 ﹤0.01% 7298
2022
Q2 		$0 Sell
3
-347
-99% -$13K ﹤0.01% 7428
2022
Q1 		$16K Sell
350
-89
-20% -$7.08K ﹤0.01% 6105
2021
Q4 		$51K Buy
439
+436
+14,533% +$65.1K ﹤0.01% 5957
2021
Q3 		$1K Sell
3
-551
-99% -$100K ﹤0.01% 6789
2021
Q2 		$108K Buy
554
+435
+366% +$107K ﹤0.01% 5281
2021
Q1 		$35K Buy
+119
New +$39.8K ﹤0.01% 5984

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo's FTH Position: Q2 2024 in Review

Wells Fargo sold out of Faeth Therapeutics (FTH) in Q2 2024, closing a stake of 7 shares — an estimated $140 sold.

Wells Fargo first reported a position in FTH in Q1 2021 and held it in 13 quarters. The position peaked at $108K in Q2 2021. 23 funds tracked by Wall St. Rank hold FTH as of Q2 2024.

  • Wells Fargo reported no remaining Faeth Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 7 Faeth Therapeutics shares in Q2 2024, an estimated $140.
  • Wells Fargo first reported a position in Faeth Therapeutics in Q1 2021 and held it in 13 quarters.
  • Wells Fargo's Faeth Therapeutics position peaked at $108K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.